On April 25, 2025, Verastem, Inc. announced a private placement with institutional investors to sell 3,429,287 shares of common stock at $7.00 each and 7,285,713 pre-funded warrants at $6.9999 each, expecting to raise approximately $75 million for funding clinical research and product launch efforts.